• News
    • Opinion Editorial
    • Videos
    • Podcasts
  • Community
    • Members
  • Discussion
  • Groups
    • View All
    • Why Join?
  • Write for us
    Sign in Sign up


    • News
      • Opinion Editorial
      • Videos
      • Podcasts
    • Community
      • Members
    • Discussion
    • Groups
      • View All
      • Why Join?
    • Write for us
    Sign in Sign up
    Romark Announces Initial Phase 3 Data Evaluating NT-300 Tablets for Mild to Moderate COVID-19

    Romark Announces Initial Phase 3 Data Evaluating NT-300 Tablets for Mild to Moderate COVID-19

    Romark announced initial results from a phase 3 trial evaluating NT-300 (nitazoxanide extended-release tablets, 300 mg) versus placebo as a treatment for mild or moderate…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    Merck Dropping $425M COVID Drug; Refocusing on Molnupiravir and Production of J & J’s COVID-19 Vaccine

    Merck Dropping $425M COVID Drug; Refocusing on Molnupiravir and Production of J & J’s COVID-19 Vaccine

    Five months after making an upfront payment of $425 million in cash to acquire OncImmune and its phase 3 COVID-19 therapeutic, CD24Fc, Merck announced it…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    Star Student Dies 24 Hours After Receiving COVID-19 Vaccine Jab But Correlation Not Proven

    Star Student Dies 24 Hours After Receiving COVID-19 Vaccine Jab But Correlation Not Proven

    Although TrialSite just reported on the temporary halt of COVID-19 vaccinations ordered by the U.S. Drug Administration (FDA) and the Centers for Disease Control (CDC) in…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    3 Comments
    Kaiser Permanente Observational Study of 50K Patient Records Shows that Active People Face Less Risk for Severe COVID-19

    Kaiser Permanente Observational Study of 50K Patient Records Shows that Active People Face Less Risk for Severe COVID-19

    A Kaiser Permanente study reveals that regular, consistent exercise activity associates with a lowered risk of severe COVID-19. Recently published in the British Journal of Sports…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    NYU Langone-led Preclinical Research Reveals Citicoline Restores Optic Nerve Signals & May Combat Glaucoma-Led Blindness

    NYU Langone-led Preclinical Research Reveals Citicoline Restores Optic Nerve Signals & May Combat Glaucoma-Led Blindness

    Important glaucoma-based research led by investigators at NYU Grossman School of Medicine reveals that a chemical known to protect nerve cells actually slows down the…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    Time to Modernize Cancer Clinical Trial Eligibility Criteria

    Time to Modernize Cancer Clinical Trial Eligibility Criteria

    How can we make cancer-focused clinical trials more inclusive while also raising the quality of overall research? That sounds like a win-win value proposition. But…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    Organicell and Oklahoma State University Enter Into Agreement To Study Zofin™ in Respiratory Diseases Caused By Virus Infections Of Pandemic Potential

    Organicell and Oklahoma State University Enter Into Agreement To Study Zofin™ in Respiratory Diseases Caused By Virus Infections Of Pandemic Potential

    Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an…

    TrialSite Staff
    TrialSite Staff April 14, 2021
    1 Comment
    Open Letter by U.S. Doctors: JAMA Ivermectin Study Is Fatally Flawed

    Open Letter by U.S. Doctors: JAMA Ivermectin Study Is Fatally Flawed

    A group of dedicated physicians recently came together to send an open letter to the medical journal JAMA. Their purpose: to declare that the recent…

    TrialSite Staff
    TrialSite Staff April 14, 2021
    8 Comments
    Brazil’s Butantan Institute Completes Phase 3 SinoVac Study & Shares Results Transparency for A Chinese Vaccine Candidate

    Brazil’s Butantan Institute Completes Phase 3 SinoVac Study & Shares Results: Transparency for A Chinese Vaccine Candidate

    Vaccines out of China were produced, and approved, rapidly but actual transparency into true efficacy has been more challenging but recently the results of a…

    TrialSite Staff
    TrialSite Staff April 14, 2021
    0 Comments
    University of Sydney-Sponsored Phase 1 Clinical Trial Evaluates Needle-Free DNA-based COVID-19 Vaccine Called COVIGEN

    University of Sydney-Sponsored Phase 1 Clinical Trial Evaluates Needle-Free DNA-based COVID-19 Vaccine Called COVIGEN

    The University of Sydney, Technovalia, and Vax4COVID recently shared their ethics committee has authorized the greenlight of a Phase 1 clinical trial of the COVIGEN COVID-19…

    TrialSite Staff
    TrialSite Staff April 14, 2021
    0 Comments
    Load More

    Read more about…

    Alzheimer Alzheimer's Disease Artificial Intelligence Autoimmune Disease Breast Cancer Cancer Cardiovascular Challenging Results China Clinical Research Clinical Research as a Care Option Clinical Trials CNS Coronavirus covid-19 COVID-19 Dementia Diabetes Digital Health Digital Media FDA Gene Therapy Immunotherapy India Investigator Content Investigator Profiles Investor Watch Ivermectin Leading Pharma Leading Sites Neurology NIH Oncology Patient Recruitment Pharma Watch Positive Results Price Watch Prostate Cancer Research SARS-CoV-2 Site Challenges Site Success Site Watch UK Vaccine

    About Us

    TRIALSITE NEWS IS  DEDICATED TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

    © 2021 - Trial Site News
    • Terms of Service
    • Privacy Policy

    TrialSite News
    159 W Broadway, Suite 200
    Salt Lake City, UT 84101

    Report Content

    Harassment or bullying behavior
    Contains mature or sensitive content
    Contains misleading or false information
    Contains abusive or derogatory content
    Anything overly promotional selling products or services

    Block Member?

    Please confirm you want to block this member.

    You will no longer be able to:

    • See blocked member's posts
    • Mention this member in posts
    • Invite this member to groups
    • Message this member
    • Add this member as a connection

    Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.